Retrospective Analysis of the French National Cohort of Patients With GAD Antibodies and Cerebellar Ataxia (Ata-GAD)

Civil Hospices of Lyon

Status: Enrolling

Conditions: GAD-receptor Antibodies-associated Encephalitis

Treatments: Other: GAD patients

Study type: Observational

Funder types: Other

Identifiers

NCT06334900

69HCL24_0297

Details and patient eligibility

About

Glutamic acid decarboxylase (GAD) is an enzyme whose function in the body is to decarboxylate glutamate to GABA. GAD65 antibodies (GAD65Ab) have been associated with type-1 diabetes (80% of new-onset patients) and various neurological conditions, mainly stiff-person syndrome (SPS/PERM), cerebellar ataxia (CA), limbic encephalitis (LE) and temporal lobe epilepsy. These syndromes all seem to result from a reduced transmission of GABA. These neurological conditions are rare and can cause symptoms like confusion, memory loss, muscle stiffness, muscle spasms, behavioural disorders, and pharmacoresistant epilepsy. When finding high levels of GAD65-Ab in the serum, a cerebrospinal fluid (CSF) sample should be taken to look for oligoclonal IgG bands and intrathecal GAD-Ab production to prove an auto-immune cause for the various neurological symptoms.

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• neurological symptoms with GAD antibody
• GAD antibody in sera and/or CSF
• patient with cerebellar ataxia

Exclusion criteria

• tested positive to another antibody.
• no data
• any test in paraneoplastic neurological syndrome and autoimmune encephalitis center

Trial design

100 participants in 1 patient group

Anti-GAD encephalitis

Description:

This is a non-interventional study involving clinical data. This data are information of medical follow up on patient like diagnosis, symptoms, biological results, cancer, treatments.

Treatment:

Other: GAD patients